MRKR — Marker Therapeutics, Inc. - Common Stock
Session close: $1.32. Regular-session share volume: 33,232,844. Change from previous close: +54.71%.
Key developments
The grant supports continued clinical development of Marker's multi-antigen recognizing T cell platform without relying on equity financing. Management also indicated additional patient data and updated response durability data are expected later this year, which could inform views on the program's progress.
Company news Marker Therapeutics Awarded $16.2 Million CPRIT Grant · Company news Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
News sources
Company news Marker Therapeutics Awarded $16.2 Million CPRIT Grant · Company news Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study